35results about "Vaccines" patented technology

The present invention is directed to a humanized BCMA single-chain variable fragment (scFv), comprising VH having the amino acid sequence of SEQ ID NO: 4 and VL having the amino acid sequence of SEQ ID NO: 5. The present invention is also directed to a BCMA chimeric antigen receptor fusion protein comprising from N-terminus to C-terminus: (i) a single-chain variable fragment (scFv) of the present invention, (ii) a transmembrane domain, (iii) at least one co-stimulatory domains, and (iv) an activating domain. This humanized BCMA-CAR-T cells have specific killing activity with secretion of cytokine IFN-gamma in CAR-T cells in vitro and in vivo.

The present invention relates to the fields of molecular biology, virology, immunology and medicine, and in particular to a preparation method for a castrating AP205 virus-like particle subunit vaccine.

This new chimeric antigen receptor (CAR) T-cell therapy effectively treats cancer while minimizing the risk of dangerous inflammatory responses such as cytokine release syndrome. [Solution] An isolated nucleic acid sequence encoding a CAR, wherein the CAR includes an antigen-binding domain specific to glypican 3 (GPC3), the antigen-binding domain has an equilibrium dissociation constant (KD) of approximately 100 nanomoles (nM) or less, and the CAR construct provides an isolated nucleic acid sequence that does not induce cytokine production in GPC3-expressing cells.

The invention belongs to the technical field of biological genetic transformation, and relates to a method for preparing recombinant foreign protein based on transient expression of fruits of cucurbitaceae crops. The efficient expression of the foreign protein is realized through the processes of constructing an instantaneous transformation vector, infecting fruits with agrobacterium and purifying the protein. The method overcomes the defects of high cost and low purity of a traditional tobacco transient expression system, has the advantages of easily available raw materials, large biomass, edibility, high safety and the like, and provides a new way for low-cost large-scale production of recombinant proteins.

The present invention relates to a method of producing a binder-toxin fusion protein comprising at least, one protein binder selected from the group consisting of an antibody, an antibody fragment or derivative retaining target binding capacity, or an antibody mimetic, optionally, a peptide linker, and at least one protein toxin or protein protoxin. The method comprises the steps of: contacting a plant cell or a whole plant with a nucleic acid construct comprising in operational linkage at least the following (A) at least one polynucleotide encoding for the protein binder, or a target binding chain or domain thereof, and either B1) a polynucleotide encoding for a cleavable peptide linker and a polynucleotide encoding for a protein toxin, or B2) a polynucleotide encoding for a protein protoxin, which protoxin comprises a cleavable domain for activation thereof, allowing the construct to integrate into the nucleus of the plant cell, or of one or more cells of the whole plant, and expressing the fusion protein encoded by the nucleic acid construct (Fig. 7).

Provided herein are cell surface receptors that include an extracellular binding domain, a transmembrane domain, an intracellular signaling domain, and a protease cleavage site disposed between the extracellular binding domain and the intracellular signaling domain. In certain aspects, the cell surface receptors are engineered cell surface receptors, such as chimeric antigen receptors (CARs). Also provided are cells that include such receptors (e.g., where the cells express the receptors on their surface) and pharmaceutical compositions including such cells. Nucleic acids that encode the cell surface receptors, cells including such nucleic acids, and pharmaceutical compositions including such cells, are also provided. Also provided are methods for regulating signaling of a cell surface receptor, and methods of using the cells of the present disclosure, including methods of using such cells to administer a regulatable cell-based therapy to an individual.

The present disclosure provides compositions and methods of treating bone cancers, e.g., osteosarcoma in a patient whose age is, for example, at least 2 years old, or at least 12 years old. The method comprises promoting the opening of Cx43 hemichannel in osteocytes by, e.g., using a composition comprising an anti-connexin 43 antibody.

In some aspects there is described formulations for the treatment of fusion-positive alveolar rhabdomyosarcoma, methods of preparing thereof, and validating their immunogenic activity.

The present invention relates to a genetically modified plant or plant cell derived from a wild-type plant or plant cell, said wild-type plant or plant cell producing at least one serine protease comprising the motif SSRGPX1LKPDX2X3APGX4SGTSMSCPHX5PX6WSPX7AX8X9SAX10MTT (SEQ ID No. 1), whereinX1 is a peptide consisting of 7 amino acid residues, X2 is I or L, X3 is T or M, X4 is a peptide consisting of 27 or 28 amino acid residues, X5 is a peptide consisting of 12 amino acid residues, X6 is T or E, X7 is S or A, X8 is V or I, X9 is K or R and X10 is I or M, wherein the proteolytic activity of the at least one serine protease in the genetically modified plant or plant cell is reduced compared to its activity in the wild-type plant or plant cell, wherein the genetically modified plant or plant cell comprises at least one exogenous nucleic acid molecule encoding for at least one protein or polypeptide of interest.

Provided herein are cancer stem cell targeted cancer vaccines and methods for treating and vaccinating against cancer. Also contained herein are regimens by which cancer stem cell targeted cancer vaccines are administered, such regimens comprising peptides, compositions, immunomodulatory agents, and emulsifiers. Also provided are the patient populations to which the regimens are to administered, and the dosages, schedules, route of administration for the regimens.

The present invention relates to a nucleic acid sequence with an elevated expression rate having at least one expression cassette for expression of a protein, wherein the expression cassette has at least one promoter element, and at least one first transcription unit that encodes at least one peptide, wherein the promoter element consists of nucleic acid sequence SEQ ID NO: 1 or of a nucleic acid sequence having at least 70% homology with SEQ ID NO: 1. The invention further relates to a vector or an isolated nucleic acid comprising at least one nucleic acid sequence of the invention in simple or repetitive form. The present invention additionally relates to an amino acid sequence comprising SEQ ID NO: 2 or an amino acid sequence having at least 70% homology with SEQ ID NO: 2, and to a cell comprising a vector of the invention or an isolated nucleic acid of the invention, or a nucleic acid sequence of the invention, or an amino acid sequence of the invention, wherein the cell is a photosynthetically active cell, especially a unicellular plant or Viridiplantae, preferably a diatom. The invention also relates to a screening method for selection of cells having an elevated expression rate of a nucleic acid sequence of the invention, and to a method of producing recombinant antibodies using a vector of the invention or an isolated nucleic acid of the invention and / or a nucleic acid sequence of the invention.

Provided is a diester lipid compound of Formula (I) or a pharmaceutically acceptable salt thereof The compound can be used to obtain lipid nanoparticles. In some embodiments, the lipid nanoparticle can comprise (a) from about 40 to about 100 mol % of the compound of Formula (I); (b) from 0 to about 10 mol % of a neutral lipid; (c) from 0 to about 50 mol % of a helper lipid; (d) from 0 to about 5 mol % of a polymer-conjugated lipid; and (e) from 0 to about 5 mol % of a hydrophobic component; wherein the mol % are based on the total lipids present in the nanoparticle. (I)

To provide a regimen capable of strongly instructing the immune system of the body to attack cancer cells.SOLUTION: The present invention is directed to regimens for administering one or more antibody-based molecules that bind to PD-1 or PD - L1 and LAG-3 (e.g., PD-1 * LAG-3 bispecific molecules), alone or in combination with antibody-based molecules that bind to tumor antigens (TA), for the treatment of cancers. The invention particularly relates to the use of such regimens in combination with a PD-1 * LAG-3 bispecific molecule.SELECTED DRAWING: Figure 10

The present invention relates to novel recombinant antibodies or antigen-binding portions thereof targeting MET, the present invention relates to an anti-MET antibody or an antigen-binding portion thereof, as well as an ADC comprising the antibody or an antigen-binding portion thereof, a composition comprising the antibody or an antigen-binding portion thereof, a composition comprising the ADC comprising the anti-MET antibody or an antigen-binding portion thereof, the use of the antibody or an antigen-binding portion thereof or the ADC or the composition comprising the anti-MET antibody or an anti-MET ADC.

The present invention provides a cell that co-expresses a first chimeric antigen receptor (CAR) and a second CAR on the surface of the cell, each CAR comprising an antigen binding domain wherein the antigen binding domain of the first CAR binds CD19 and the antigen binding domain of the second CAR binds CD22.

Embodiments of the present disclosure pertain generally to head and neck squamous cell carcinomas (HNSCCs) related to human papillomavirus subtype 16 (HPV16) infections. More particularly, the present disclosure provides novel immunogenic epitopes from HPV16 E2, E6 and E7 antigens restricted by common human leukocyte antigen (HLA) alleles for the diagnosis and treatment of HNSCC. The HPV16 epitopes identified in the present disclosure can be used in combination with blockade of HPV16+ HNSCC-specific checkpoints for targeted immunotherapy.

This disclosure provides pharmaceutical compositions comprising a fixed dose of a dimeric T cell modulatory proteins (DTMPs) comprising peptide-MHC complexes (pMHCs) that present a peptide other than a peptide of an HPV protein or a WT1 protein, and methods of treating an individual in need thereof by administering a fixed dose of a DTMP. The pharmaceutical compositions comprise a fixed dose of a DTMP, and the methods comprise administering a fixed dose of a DTMP to an individual regardless of the weight of the individual. Also provided are kits useful for administering a fixed dose of the DTMP.

A composition includes a contraceptive chimeric virus-like particle with an antigenic carrier domain and one or more antigenic regions from a sperm cell in the antigenic carrier domain, with the antigenic carrier domain including human papillomavirus L1 capsid protein and the antigenic regions including one or more structural elements of the Catsper ion channel complex. When administered to a patient, the contraceptive vaccine stimulates production of anti-sperm antibodies that, upon binding to a sperm cell, inhibit the sperm cell's motility and thus inhibit the ability of the sperm cell to fertilize an egg cell. The induced immunoinfertility of the composition can be reversed for brief or extended lengths of time by overdosing the patient with a reversal agent lacking the antigenic carrier domain but having a protein sequence substantially identical to that of the one or more antigenic regions to sequester the anti-sperm antibodies.

The present disclosure relates to transgenic tomato plants, which have been transformed to produce a fragment of respiratory syncytial virus (RSV) F protein, and the plant-optimized plasmids that produce such transgenic tomato plants. In some aspects, the transgenic tomato plant expresses the ectodomain of RSV F protein. In certain embodiments, the fragment of RSV F protein comprises the ectodomain of RSV F protein, and the p27 region of the RSV F protein is replaced with a sequence-specific linker region comprising the amino acid sequence of GSGSGRSLG. Also described are compositions comprising an extraction from a fruit of the transgenic tomato plant, wherein the extraction from the fruit of the transgenic tomato plant comprises the fragment of RSV F protein.

The present disclosure relates to compositions and methods for treating cancer using chimeric antigen receptor T cells that target glypican 3.

The present description relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present description relates to the immunotherapy of cancer. The present description further relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

To provide a therapeutic agent for treating metastatic brain tumor.SOLUTION: A therapeutic agent for metastatic brain tumor, comprising, as an active ingredient, an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents a binding site to an antibody) is bound to an antibody via a thioether bond, and / or a method for treating metastatic brain tumor, comprising administering the antibody-drug conjugate to an individual in need of treatment of metastatic brain tumor: SELECTED DRAWING: Figure 9

Modified coronavirus spike (S) proteins, virus-like particles (VLPs) comprising the modified S proteins, and nucleic acids encoding the modified S proteins are provided. Methods for producing the modified S proteins and VLPs in a host or host cell are also described. The modified S protein can comprise a transmembrane domain (TM) or portion of a TM and a cytosolic tail (CT) or portion of a CT, wherein the CT or portion of the CT is derived from an influenza hemagglutinin (HA) protein, and the TM or portion of the TM is heterologous to the CT or portion of the CT. Additionally, methods for inducing immunity to coronavirus infection in a subject are described, comprising administering to the subject a composition comprising a modified coronavirus (S)-protein or VLP.

The present invention relates in various aspects to the development and use of synthetic chimeric vaccinia viruses or compositions comprising such viruses, as well as systems and methods for producing such synthetic chimeric vaccinia viruses. The synthetic chimeric vaccinia viruses are particularly well suited as viral vaccines or to produce oncolytic reactions and pharmaceutical formulations.

The transgenic plants expressing one or more antagonist IL-10R peptides and anti-IL-10 single domain antibodies that stimulate or modulate the immune system and improve gastrointestinal physiology of an animal fed the transgenic plants or tissues thereof and the genes encoding the antagonist IL-10R peptides and anti-IL-10 single domain antibodies are described. The animal feed additives and animal feed incorporating the transgenic plants or tissues thereof are also described. Methods of stimulating or modulating an animal's immune system, improving an animal's gastrointestinal physiology, improving animal performance by using the transgenic plants or tissues thereof, and treating animals infected with a gastrointestinal pathogen are provided.

Disclosed are monoclonal antibodies against Chikungunya virus having enhanced effector function and efficacy, methods of producing them, and methods of treatment of Chikungunya viral infection using the antibodies.

The present invention relates to a novel recombinant antibody or antigen-binding portion thereof targeting MET, as well as ADCs comprising this antibody or antigen-binding portion thereof, compositions comprising this antibody or antigen- binding portion thereof, compositions comprising ADCs comprising said anti-MET antibody or antigen-binding portion thereof, the use of said antibody or antigen- binding portion thereof or of said ADCs or of said compositions comprising anti- MET antibody or anti-MET ADC.

To provide a therapeutic agent for metastatic brain tumor.SOLUTION: A therapeutic agent for metastatic brain tumor, comprising, as an active ingredient, an antibody-drug conjugate in which a drug linker represented by the following formula (wherein A represents a binding site to an antibody) is bound to an antibody via a thioether bond, and / or a method for treating metastatic brain tumor, comprising administering the antibody-drug conjugate to an individual in need of treatment of metastatic brain tumor: SELECTED DRAWING: Figure 9

The invention relates to immunotherapeutic treatment of cancer. In particular, the invention relates to methods of treating cancer carrying a histone H3 K27M (H3K27M) mutation (e.g., diffuse midline glioma with H3K27M mutation) using immunotherapeutic compositions comprising immune cells engineered to express GD2-specific chimeric antigen receptors.

The present invention relates to a method of producing a binder-toxin fusion protein comprising at least, one protein binder selected from the group consisting of an antibody, an antibody fragment or derivative retaining target binding capacity, or an antibody mimetic, optionally, a peptide linker, and at least one protein toxin or protein protoxin. The method comprises the steps of: contacting a plant cell or a whole plant with a nucleic acid construct comprising in operational linkage at least the following (A) at least one polynucleotide encoding for the protein binder, or a target binding chain or domain thereof, and either B1) a polynucleotide encoding for a cleavable peptide linker and a polynucleotide encoding for a protein toxin, or B2) a polynucleotide encoding for a protein protoxin, which protoxin comprises a cleavable domain for activation thereof, allowing the construct to integrate into the nucleus of the plant cell, or of one or more cells of the whole plant, and expressing the fusion protein encoded by the nucleic acid construct (Fig. 7).